General Mills, Inc. vs Johnson & Johnson — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 35.5× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Johnson & Johnson for 129 Days on average.
| GIS | JNJ | |
|---|---|---|
Market Cap | $17.43B | $618.09B |
Volume | 16,554,362 | 6,050,983 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $278.43 |
52-Week Low | $31.67 | $186.00 |
Typical Hold Time | 106 Days | 129 Days |
Enterprise Value | $30.61B | $646.37B |
Dividend Yield | 7.49% | 2.09% |
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, but faces fundamental challenges with negative net income margin (-4.89%) and ROE (-10.55%) for 2026. The stock shows bearish technical signals with mixed earnings performance - missing Q4 2025 estimates but beating Q2 2026. Recent CEO transition to Dana McNabb and a $3 billion cost-saving initiative aim to stabilize operations amid declining revenue trends from $19.5B (2025) to $18.3B (2026).
The stock presents a high-yield opportunity with a $0.61 dividend, but significant risks include persistent margin pressure and rising debt-to-asset ratio (45% in 2025). Analyst consensus is cautious with 61% hold ratings, though the $36 price target suggests 10% upside. Investors should weigh the dividend stability against fundamental deterioration and leadership transition execution risks.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →